Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 893 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Shorter, More Intensive Radiation Safe after Surgery for Prostate Cancer November 18, 2021 Cómo pueden sobrellevar la ansiedad provocada por una exploración las personas... August 4, 2022 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... April 1, 2026 Load more HOT NEWS Adding Durvalumab to First-Line Platinum-Based Chemotherapy Followed by Maintenance Durvalumab With... Study Tackles Key Questions about Liver Transplants for People with Liver... We have a Deal: What does the new UK-EU relationship mean... FDA Grants Traditional Approval to Encorafenib for mCRC with a BRAF...
